Yahoo Finance

Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial

Six-month safety and effectiveness data for the 250 randomized patients to support PMA submission to FDA; enrollment to continue to 400 The AccuCinch System is an investigational device designed to ...
Business Wire

Ancora Heart Inc. and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patients

Use of artificial intelligence technology efficiently identifies eligible patient candidates for pivotal clinical trial; program launched at The Christ Health Network SANTA CLARA, Calif. & ALISO VIEJO ...
Business Wire

Ancora Heart Enrolls First Patient in the CORCINCH-HF Study

Pivotal Trial to Evaluate Safety and Efficacy of AccuCinch® Ventricular Restoration System in Heart Failure Patients with Reduced Ejection Fraction SANTA CLARA, Calif.--(BUSINESS WIRE)--Ancora Heart, ...
TCTMD

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

Photo Credit: Adapted from Jorde U. AccuCinch: outcomes of transcatheter lv volume reduction in HFrEF with a transcatheter ventricular restoration system. Presented at: THT 2023. Boston, MA. BOSTON, ...
Healio

Novel percutaneous LV repair system shows promise in systolic HF

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Early clinical data suggest that an investigational percutaneous device designed to directly ...
Yahoo Finance

Ancora Heart Inc. Reports Two-Year Results Demonstrating Sustained Benefits of AccuCinch® System in Heart Failure Patients

SANTA CLARA, Calif., October 23, 2025--(BUSINESS WIRE)--Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that ...
TCTMD

Design and Rationale of the CORCINCH-HF Pivotal Study

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...
Healio

LV implant to treat symptoms of resistant HFrEF nets FDA breakthrough device designation

Please provide your email address to receive an email when new articles are posted on . Ancora Heart Inc. announced that the FDA granted breakthrough device designation to its transcatheter left ...
Albuquerque Journal

Lovelace joins groundbreaking clinical trial focused on heart failure treatment

The Heart Hospital of New Mexico at Lovelace Medical Center has joined a potentially groundbreaking clinical trial addressing heart failure. The CORCINCH-HF study, which the Lovelace Health System ...
PharmiWeb

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restoration System

Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection Fraction SANTA CLARA, Calif ...
MD&M East

Ancora Heart Has Raised $80M to Address HF

Ancora Heart, a private company focused on the treatment of heart failure, has raised an $80 million equity financing. The Santa Clara, CA-based company is developing the AccuCinch Ventricular ...